Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519902 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
A Phase 3 study, sponsored by Dompé Farmaceutici S.p.A.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07519902: Recruiting Phase 3 study, sponsored by Dompé Farmaceutici S.p.A.
NCT07519902 is a Phase 3 study that is actively recruiting participants, run by Dompé Farmaceutici S.p.A. The registered enrollment target is 150 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07519902, a Phase 3 study, is actively recruiting participants, sponsored by Dompé Farmaceutici S.p.A.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of complete epithelial healing after 4 weeks of treatment. The study is comprised of 3 periods: an 8-week initial treatment period (Day 1 to Week 8), an 8-week extension treatment period (Week 9 to Week 16), and a 24-week follow-up period (Week 17 to Week 40).
Interventions
- OTHER Vehicle
- DRUG Cenegermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT07519902 shows while recruiting
NCT07519902 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT07519902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07519902 about?
NCT07519902 is a clinical study titled "An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED". This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of complete epithelial...
What is the current status of trial NCT07519902?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06-02. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07519902?
The interventions under investigation include: Vehicle (OTHER), Cenegermin (DRUG).
Who is sponsoring clinical trial NCT07519902?
This trial is sponsored by Dompé Farmaceutici S.p.A, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07519902's enrollment target sits among peer trials
150 1519th of 2000 higher than 455 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI